The observation that the knockdown or the pharmacologic inhibition of PKM2 by shikonin in hepatocellular carcinoma cell lines resulted in a less proliferative and aggressive phenotype as well as improved drug sensitivity to both doxorubicin and cisplatin [64] emphasises the relevance of PKM2 as a therapeutic target. The gene discussed is PKM; the disease is hepatocellular carcinoma.